ACUTE MYELOGENOUS LEUKEMIA AND AGING
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Acute myelogenous leukemia (AML) is a devastating disease that afflicts the elderly more frequently than the young. Ironically, many of the recent therapeutic advances are not deemed suitable for the very population of patients that suffers most from this illness. This point raises competing issues. On one hand, the effect of modern therapy for AML in the elderly may be skewed by the underrepresentation of the elderly in clinical trials. Indeed, Ferrara showed that only 55% of patients over the age of 60 years were enrolled in clinical trials, as compared with more than 90% of younger patients.12 In leukemia, specifically, less than 10% of clinical trial participants were older than 65 years, even though this cohort represents more than 55% of patients with leukemia.65 On the other hand, elderly patients enrolled in prospective randomized studies may not be representative of the total elderly AML population but may instead represent a cohort of healthier patients. A prospective British study of AML in the elderly found that only 89 of 200 patients newly diagnosed with AML were considered fit enough to receive treatment with curative intent. This finding emphasizes that the elderly are frequently afflicted with comorbidities that preclude aggressive therapy.59 The definition of elderly is difficult to determine, because it involves biologic considerations and chronologic age. Most therapeutic trials in the United States include patients aged 55 years or older in this category. Bone marrow transplantation, whether allogeneic or autologous, rarely is offered to individuals over the age of 60 years. This article does not attempt to define elderly with any degree of precision but includes the age group of 55 to 65 years, the young-old, in the elder category. Certainly, the Medicare definition of elderly (65 years of age or older) is also acceptable. This article reviews the biologic and clinical characteristics of AML in the elderly population and the treatment options that have emerged during the past several years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
Cited by
Management of Cancer in the Older Person: A Practical Approach
Balducci, L., & Extermann, M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-3-224 · Cited by 939
Talarico, L., Chen, G., & Pazdur, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.175 · Cited by 727
Survival for older patients with acute myeloid leukemia: a population-based study
Oran, B., & Weisdorf, D. J. (2012) · Haematologica · doi:10.3324/haematol.2012.066100 · Cited by 423
How ageing processes influence cancer
de Magalhães, J. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3497 · Cited by 367
EORTC elderly task force position paper: Approach to the older cancer patient
Pallis, A. G., Fortpied, C., Wedding, U., Van Nes, M. C., Penninckx, B., Ring, A., Lacombe, D., Monfardini, S., Scalliet, P., & Wildiers, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.022 · Cited by 340
Metadata
- Authors
- Lancet, J. E., Willman, C. L., & Bennett, J. M.
- Venue
- Hematology/Oncology Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2000-02
- Volume
- 14
- Issue
- 1
- Pages
- 251-267
- ISSN
- 0889-8588 (ISSN-L)
- OpenAlex
- W141365462
- Cited by
- 73
- References
- 1
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ACUTE MYELOGENOUS LEUKEMIA AND AGING. https://app.cochat.ai/papers/10.1016/s0889-8588(05)70287-2
- The paper
- Lancet, J. E., Willman, C. L., & Bennett, J. M. (2000). ACUTE MYELOGENOUS LEUKEMIA AND AGING. Hematology/Oncology Clinics of North America. https://doi.org/10.1016/s0889-8588(05)70287-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.